Microfluidic chip for rapid and selective isolation of tumor-derived extracellular vesicles for early diagnosis and metastatic risk evaluation of breast cancer

The epithelial-to-mesenchymal transition (EMT) index in cancer is a complementary approach for estimating metastatic risk. Considering the demand for evaluating metastatic risk based on liquid biopsies, tumor-derived extracellular vesicles (EVs) can be exploited to generate the EMT index. For the ge...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Biosensors & bioelectronics 2021-11, Vol.192, p.113495-113495, Article 113495
Hauptverfasser: Gwak, Hogyeong, Park, Sunyoung, Kim, Junmoo, Lee, Jeong Dong, Kim, In-Soo, Kim, Seung-Il, Hyun, Kyung-A, Jung, Hyo-Il
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The epithelial-to-mesenchymal transition (EMT) index in cancer is a complementary approach for estimating metastatic risk. Considering the demand for evaluating metastatic risk based on liquid biopsies, tumor-derived extracellular vesicles (EVs) can be exploited to generate the EMT index. For the generation of EVs-based EMT index, it is essential to selectively isolate each epithelial cell and mesenchymal cell-derived EVs. This study proposes a novel microfluidic chip for selectively separating two types of EVs in an efficient and timely manner. The microfluidic chip is fully integrated with a micromixer for the creation of efficient collision between EVs and specific antibody-coated microbeads (7 and 15 μm in diameter) and a hydrodynamic particle separator for the stratification of EVs bound microbeads according to the sizes of microbeads. Using this chip, over 90% of EVs expressing the epithelial marker (epithelial cell adhesion molecule, EpCAM) and the mesenchymal marker (CD49f) can be selectively isolated within 6.7 min per 100 μL of sample volume. The clinical relevance of EMT is investigated using plasma samples from 20 breast cancer patients and 10 age-matched controls. The EMT index produced from the microfluidic chip is in a good agreement with the conventional tissue-based EMT index and is significantly high in patients with aggressive breast cancer subtypes, compared with healthy controls. In addition, the patients with high scores on the EMT index (≥5) shows recurrence within 5 years after adjuvant treatment. Predicting EMT-index-based metastatic risk using our microfluidic chip can be beneficial for cancer diagnosis and prognosis. •An integrated microfluidic chip (HO-MOFF) is introduced for specifically separating two types of EV associated with cancer.•The HO-MOFF chip separates each type of EVs in a short period (6.7 min/100 μL plasma sample and over 90% efficiency).•The ratio of epithelial to mesenchymal transition related EVs (EMT index) can be generated by the HO-MOFF in a rapid and reliable manner.•The breast cancer patients are successfully distinguished from healthy controls by the EVs-based EMT index.•The EVs-based EMT index reflects the statuses of the tumors and can be applied to the prediction of metastatic risk.
ISSN:0956-5663
1873-4235
DOI:10.1016/j.bios.2021.113495